Seasonal Affective Disorder Therapeutics Market
Global Seasonal Affective Disorder Therapeutics Market Size, Share & Trends Analysis Report, By Disorder Type (Unipolar Disorder and Bipolar Disorder), By Treatment Type (Medications, Light Therapy, and Others) and Forecast, 2020-2026
The global seasonal affective disorder therapeutics market is estimated to witness potential growth during the forecast period. The major factors contributing to the growth of the market include the rising awareness regarding mental health and rising prevalence of seasonal affective disorder and depression. Rising insurance claims for mental health has shown emerging awareness regarding mental health. As per the Association of British Insurers (ABI), in 2017, mental health was the most common cause of claim on income protection policies in the UK. As a result, the ABI engage with the health and protection industry and charities to promote remarkable access to insurance for individuals suffering from mental health conditions.
Emerging nations have also been started emphasizing on mental health owing to the increasing suicide rates. For instance, in India, the Insurance Regulatory and Development Authority of India (IRDAI) has directed the insurers to offer medical insurance to cover mental illness treatments. According to Sec 21(4) of the Mental Healthcare Act, 2017, every medical insurer will offer coverage to treat mental illness the same as available for the treatment of physical illness. In May 2018, this mental healthcare act 2017 came into appearance. These kinds of initiatives are supporting to increase awareness among people regarding mental health, which in turn, increases the demand for seasonal affective disorder treatment.
The seasonal affective disorder is a mental health condition caused by the changing in seasons. It is a subtype of bipolar disorder and unipolar or major depressive disorder. People suffering from the seasonal affective disorder have signs and symptoms of either bipolar disorder or unipolar disorder only during certain months of the year. Unipolar disorder is more common compared to bipolar disorder among people suffering from the seasonal affective disorder. This condition normally starts in a person's twenties or thirties. Medications and light therapy are used for the treatment of the condition.
Market Segmentation
The global seasonal affective disorder therapeutics market is segmented based on disorder type and treatment type. Based on disorder type, the market is classified into unipolar disorder and bipolar disorder. Based on treatment type, the market is classified into medications, light therapy, and others.
Medications account for a significant share in the market
Medications are the most commonly used treatment alternative for seasonal affective disorder. Antidepressants are usually prescribed for the treatment of depression and are also often used for the treatment of severe cases of seasonal affective disorder. Selective serotonin reuptake inhibitors (SSRIs) are highly preferred antidepressants for the treatment of the seasonal affective disorder. SSRIs works to enhance the level of the hormone serotonin in the brain, which can support lift the patient’s mood. SSRIs medications include fluoxetine (Prozac), citalopram (Celexa), escitalopram (Lexapro), sertraline (Zoloft), duloxetine (Cymbalta), and paroxetine (Paxil, Pexeva).
Global Seasonal Affective Disorder Therapeutics Market Share by Treatment Type, 2019 (%)
Regional Outlook
Geographically, the market is classified into North America, Europe, Asia-Pacific, and Rest of the World (RoW). North America seasonal affective disorder therapeutics market is being significantly driven by the considerable awareness regarding mental health and better insurance coverage for mental health in the region. In addition, the demand for antidepressants is further driving the market growth in the region. As per the American Psychological Association (APA), there was a 64% increase in people using antidepressants reported between 1999 and 2014. This, in turn, represents high awareness among people regarding mental disorder treatment in the country, which thereby contributing to the market growth in the region.
Global Seasonal Affective Disorder Therapeutics Market Growth, by Region 2020-2026
Market Players Outlook
The major players in the market include Otsuka Pharmaceutical Co., Ltd., AbbVie, Inc., Pfizer Inc., Koninklijke Philips N.V., and Active Wearables GmbH. The strategies adopted by the market players include mergers and acquisitions, product launches, and partnerships and collaborations. For instance, in February 2019, Active Wearables, an Austrian medtech start up launched Pocket Sky, a wearable which is designed to tackle conditions occurred due to poor access to sunlight and time shifts. It worn as a pair of glasses and gives off blue light to mimic sunlight, apparently controlling melatonin production. Light therapy can be difficult to achieve while travelling or at work. As a result, Pocket Sky enable patients to harness the benefits of light therapy with the use of a small wearable. Wearables demand is expected to emerge for mental health conditions owing to the increasing innovations in wearable devices. This, in turn, will offer new hope for the treatment of the seasonal affective disorder.
The Report Covers
- Market value data analysis of 2019 and forecast to 2026.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global seasonal affective disorder therapeutics market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. Stakeholders
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules and Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Otsuka Pharmaceutical Co., Ltd.
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. AbbVie Inc.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Pfizer Inc.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Koninklijke Philips N.V.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Active Wearables GmbH
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities
5. Market Segmentation
5.1. Global Seasonal Affective Disorder Therapeutics Market by Disorder Type
5.1.1. Unipolar Disorder
5.1.2. Bipolar Disorder
5.2. Global Seasonal Affective Disorder Therapeutics Market by Treatment Type
5.2.1. Medications
5.2.1.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
5.2.1.2. Monoamine Oxidase Inhibitors (MAOIs)
5.2.1.3. Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
5.2.1.4. Others
5.2.2. Light Therapy
5.2.3. Others
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. AbbVie Inc.
7.2. Active Wearables GmbH
7.3. Aura Day Light
7.4. Bristol-Myers Squibb Co.
7.5. Carex Health Brands
7.6. Eli Lilly & Co.
7.7. F. Hoffmann-La Roche AG
7.8. GlaxoSmithKline plc
7.9. H. Lundbeck A/S
7.10. Koninklijke Philips N.V.
7.11. Lucimed SA
7.12. Mylan N.V.
7.13. Novalogy, Inc.
7.14. Novartis International AG
7.15. Otsuka Pharmaceutical Co., Ltd.
7.16. Pfizer Inc.
7.17. Shine-Mart Ltd. (Duronic)
7.18. Teva Pharmaceutical Industries Ltd.
7.19. Verilux, Inc.
1. GLOBAL SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISORDER TYPE, 2019-2026 ($ MILLION)
2. GLOBAL UNIPOLAR DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
3. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
4. GLOBAL SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2019-2026 ($ MILLION)
5. GLOBAL MEDICATIONS IN SEASONAL AFFECTIVE DISORDER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
6. GLOBAL LIGHT THERAPY IN SEASONAL AFFECTIVE DISORDER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
7. GLOBAL SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
8. NORTH AMERICAN SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
9. NORTH AMERICAN SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISORDER TYPE, 2019-2026 ($ MILLION)
10. NORTH AMERICAN SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2019-2026 ($ MILLION)
11. EUROPEAN SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
12. EUROPEAN SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISORDER TYPE, 2019-2026 ($ MILLION)
13. EUROPEAN SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2019-2026 ($ MILLION)
14. ASIA-PACIFIC SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
15. ASIA-PACIFIC SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISORDER TYPE, 2019-2026 ($ MILLION)
16. ASIA-PACIFIC SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2019-2026 ($ MILLION)
17. REST OF THE WORLD SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISORDER TYPE, 2019-2026 ($ MILLION)
18. REST OF THE WORLD SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2019-2026 ($ MILLION)
1. GLOBAL SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET SHARE BY DISORDER TYPE, 2019 VS 2026 (%)
2. GLOBAL SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET SHARE BY TREATMENT TYPE, 2019 VS 2026 (%)
3. GLOBAL SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
4. US SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
5. CANADA SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
6. UK SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
7. FRANCE SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
8. GERMANY SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
9. ITALY SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
10. SPAIN SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
11. ROE SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
12. INDIA SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
13. CHINA SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
14. JAPAN SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
15. REST OF ASIA-PACIFIC SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
16. REST OF THE WORLD SEASONAL AFFECTIVE DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
